Press releases

Sabinsa’s Boswellin® super reported In japanese study to show improvement in knee pain
December 13, 2016

A study evaluating the effects of Sabinsa’s Boswellin® Super (BSR) on knee pain reduction was recently published in the European Journal of Biomedical and Pharmaceutical Sciences (2016, Volume 3, Issue 10, 293-298): The Effect of Boswellin Super on Knee Pain in Japanese Adults: A randomized, double-blind, placebo-controlled trial…

Sabinsa corporation defends proprietary distinctiveness in its brand “Boswellin”
September 12, 2016

In line with its commitment to enforce intellectual property and to honour the trust of millions of customers vested in its branded ingredients, Sabinsa Corporation successfully defended its proprietary rights on European Union Community trademark. 000379743 for “Boswellin” in international class 05. he legal action was jointly initiated by Sabinsa Corporation, NJ, USA and its trademark license Walmark, a.s., Oldřichovice, Třinec…

Study on Sabinsa's boswellia cream published in clinical dermatology US clinical drug trials set to begin
July 16, 2014

A study on Sabinsa’s Boswellia cream for treatment of psoriasis, Clinical Evaluation of AKBBA in the management of psoriasis, was published in Clinical Dermatology 2014; 2 (1): 17-24. US clinical trials, intended to have AKBBA eventually approved as a drug by FDA for treatment of psoriasis, will begin in the near future. This will be a significant step for a nutraceutical company in USA…

Sabinsa to host Boswellin® PS vendor works at supplyside west
October 11, 2010

Sabinsa Corporation will present a Vendor Works presentation on their proprietary Boswellin® PS at SupplySide West on Wednesday October 20, 2010, 4:00-4:50 pm in Galileo Rm. 901, Venetian Hotel, Las Vegas, NV. Lakshmi Prakash, Ph.D., Vice President of Innovation & Business Development, Sabinsa Corporation, is slated to give the presentation: Boswellin PS: The Next Generation Boswellia serrata Extract…

Sabinsa introduces Boswellin® PS - full spectrum bioactive
March 01, 2010

Sabinsa introduces Boswellin® PS*, a natural extract from the gum resin of Boswellia serrata (Indian frankincense), with enhanced water solubility and joint health support potential. Sabinsa will debut Boswellin® PS at SupplyExpo booth # 313 at the Anaheim Convention Center, in Anaheim, California March 12 – 14, 2010…

Sabinsa corporation proposes industry redefinition of standards on boswellic acids, publishes booklet Boswellin®: Redefining our standards
May 31, 1999

Sabinsa Corporation’s founder Dr. Muhammed Majeed and his scientific staff have co-authored a booklet entitled “Boswellin®: Redefining Our Standards” to recommend that the supplement industry redefine its references to this ingredient. In 1991, Sabinsa Corporation pioneered Boswellin®, a standardized extract containing boswellic acids, for the U.S. market. The prevalently used nomenclature for the anti-inflammatory constituents in Boswellia serrata extracts…

Sabinsa’s Boswellin® super reported In japanese study to show improvement in knee pain
December 13, 2016

A study evaluating the effects of Sabinsa’s Boswellin® Super (BSR) on knee pain reduction was recently published in the European Journal of Biomedical and Pharmaceutical Sciences (2016, Volume 3, Issue 10, 293-298): The Effect of Boswellin Super on Knee Pain in Japanese Adults: A randomized, double-blind, placebo-controlled trial…

Sabinsa corporation defends proprietary distinctiveness in its brand “Boswellin”
September 12, 2016

In line with its commitment to enforce intellectual property and to honour the trust of millions of customers vested in its branded ingredients, Sabinsa Corporation successfully defended its proprietary rights on European Union Community trademark. 000379743 for “Boswellin” in international class 05. he legal action was jointly initiated by Sabinsa Corporation, NJ, USA and its trademark license Walmark, a.s., Oldřichovice, Třinec…

Study on Sabinsa's boswellia cream published in clinical dermatology US clinical drug trials set to begin
July 16, 2014

A study on Sabinsa’s Boswellia cream for treatment of psoriasis, Clinical Evaluation of AKBBA in the management of psoriasis, was published in Clinical Dermatology 2014; 2 (1): 17-24. US clinical trials, intended to have AKBBA eventually approved as a drug by FDA for treatment of psoriasis, will begin in the near future. This will be a significant step for a nutraceutical company in USA…

Sabinsa to host Boswellin® PS vendor works at supplyside west
October 11, 2010

Sabinsa Corporation will present a Vendor Works presentation on their proprietary Boswellin® PS at SupplySide West on Wednesday October 20, 2010, 4:00-4:50 pm in Galileo Rm. 901, Venetian Hotel, Las Vegas, NV. Lakshmi Prakash, Ph.D., Vice President of Innovation & Business Development, Sabinsa Corporation, is slated to give the presentation: Boswellin PS: The Next Generation Boswellia serrata Extract…

Sabinsa introduces Boswellin® PS - full spectrum bioactive
March 01, 2010

Sabinsa introduces Boswellin® PS*, a natural extract from the gum resin of Boswellia serrata (Indian frankincense), with enhanced water solubility and joint health support potential. Sabinsa will debut Boswellin® PS at SupplyExpo booth # 313 at the Anaheim Convention Center, in Anaheim, California March 12 – 14, 2010…

Sabinsa corporation proposes industry redefinition of standards on boswellic acids, publishes booklet boswellin®: Redefining our standards
May 31, 1999

Sabinsa Corporation’s founder Dr. Muhammed Majeed and his scientific staff have co-authored a booklet entitled “Boswellin®: Redefining Our Standards” to recommend that the supplement industry redefine its references to this ingredient. In 1991, Sabinsa Corporation pioneered Boswellin®, a standardized extract containing boswellic acids, for the U.S. market. The prevalently used nomenclature for the anti-inflammatory constituents in Boswellia serrata extracts…